In a controversial move, Dr. Vinay Prasad, a prominent FDA official, has once again rejected a vaccine application, this time for Moderna's flu vaccine. But what's causing a stir is that Prasad's decision goes against the recommendations of his own staff, who were prepared to review the vaccine. This isn't the first time Prasad has overruled his team, sparking debates about the FDA's vaccine approval process.
The Inside Story:
Sources within the FDA revealed that the career scientists' team had thoroughly assessed Moderna's application and deemed it ready for review. David Kaslow, the vaccine office director, even provided a comprehensive memo outlining the reasons for proceeding with the evaluation. However, Prasad's decision to reject the application has left many scratching their heads.
A Divided Review Team?
According to Andrew Nixon, a Health and Human Services Department spokesperson, the review team had differing opinions. But was this a case of genuine scientific debate or something more complex? The FDA's process is under the spotlight, with some questioning whether external factors influenced Prasad's decision.
The Reporter's Perspective:
Lizzy Lawrence, STAT's FDA coverage lead, brings her expertise to the forefront. With a background in medical devices reporting, Lawrence is a trusted source for insights into the FDA's workings. Reach out to her via Signal at lizzylaw.53 to delve deeper into this intriguing story.
Unlock the Full Story:
STAT+ subscribers can access the exclusive article, along with in-depth analysis, newsletters, and premium events. Don't miss out on the latest developments in this ongoing saga. Subscribe now to join the discussion and gain a comprehensive understanding of this FDA controversy.
